drugset / Trial / NCT02238210
Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Study to determine the safety of Atrovent Nasal Spray 0.06% in pediatric patients (ages 2-5 years) with symptoms of rhinorrhea associated with a naturally occurring common cold or from symptoms of rhinorrhea associated with allergies
Timeline
- Start
- 2002-12
- Primary completion
- 2003-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipratropium | Small molecule | 0.06 % | Intranasal |
Indications
No indication recorded.